pharma

Tight budget pharmaceuticals

Tight budget pharmaceuticals

Company develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally. Established in 1994 in Saudi Arabia, Tight budget pharmaceuticals

’ fast growth has allowed it to become a global company, with a strong focus on the Middle East and North Africa region. Today, Tabuk Pharmaceuticals is present in over 20 markets and employs approximately 1,500 employees. Tabuk Pharmaceuticals operates in multiple therapeutic areas including CNS, cardiovascular, anti-infectives, respiratory, and muscular skeletal system.

Tight budget pharmaceuticals

distinctive marketing capabilities, state of the art manufacturing facilities, broad product portfolio, deep understanding of pharmaceutical regulations, and strong partnerships and affiliations, helped create a leading pharmaceutical player in the MENA region. Its standing as one of the largest Arab pharmaceutical companies, and the first Saudi Pharmaceutical Company to obtain EU-GMP certification, is a tribute to competencies and know-how.

Tight budget pharmaceuticals

aim is to consistently exceed the demands of our patients by providing them with the best quality drugs at affordable prices.

Tight budget pharmaceuticalsis a fully owned subsidiary of Astra Industrial Group (AIG), a publicly traded company on the Saudi stock exchange.

Company – Tight budget pharmaceuticals

Strategy

p4To increase its market share and expand its footprint throughout the MENA region, Tabuk Pharmaceuticals’ strategy focuses on both organic and inorganic growth. Tight budget pharmaceuticals

strives to increase efficiency and implement best practices across functions, with a focus on R&D, Manufacturing, and Sales & Marketing. Tight budget pharmaceuticals

portfolio is deployed across the region, while being continuously enriched with innovative molecules. Inorganic opportunities, including in-licensing deals and M&A, are also a significant component of Tight budget pharmaceuticals

growth strategy.

Vision, Mission and Values

Our
VISION

To become a leading pharmaceutical manufacturing company in the MENA region, dedicated to providing the highest quality drugs

Our
MISSION

To better the lives of our patients and our people

 

Our
VALUES

· Quality Focus

· Impact Oriented

· Collaboration

· Courage to do what’s right

· Transparency

· Respect for work life balance

· Efficiency

· Personal growth

· Autonomy

· Ethical

Offering High Quality, Affordable Pharmaceuticals

p2We are a vertically integrated company that develops, manufactures and markets Generic, Branded Generic, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. We have a large portfolio of over 500 molecules that cover multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Our presence extends across therapies and includes Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. Biotech and Vaccines are two new segments that we have begun investing in. A stronger presence in these areas will add significant depth to the existing product pipeline.

Through our unique hybrid business model involving Daiichi Sankyo, we also introduce innovator products in markets around the world.

Driven by Innovation

Our continued focus on Research & Development (R&D) has resulted in several regulatory approvals in both developed and emerging markets. We have multiple R&D centres in Gurgaon, Haryana, India with facilities for generic and innovative research. Our scientists have given India its first New Chemical Entity (NCE) that was launched on April 25, 2012. The product, SynriamTM, is a new age cure for Malaria. With a strong focus on research in generics, we are increasingly working on more complex and specialised areas.

Delivering Value

p3Our business philosophy, based on delivering value to our stakeholders, constantly inspires our people to innovate, excel and set new global benchmarks. Our multicultural workforce, comprising more than 14,600 employees of over 50 nationalities, gives us the strength to make quality healthcare accessible to people around the world. We remain committed to aggressively pursuing our mission of ‘Enriching lives globally, with quality and affordable pharmaceuticals’.

Public Policy

p1Policy-making and legislation have an essential impact on our business. Likewise, our activities have an influence on society and the public sector. We believe that sharing our expertise and communicating our positions contribute responsibly to policy-making and are part of our engagement as corporate citizen.

Our knowledge and expertise is offered to policy-makers and other relevant stakeholders on a wide range of issues affecting our business by engaging in constructive dialogue. We work and cooperate with health policy experts and trade organizations on national and global scale, like the German Association of Research-based Pharmaceutical Companies (vfa), the European Federation of Pharmaceutical Industries (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

The guiding principle we apply to our corporate public affairs activities is transparency. As part of our ongoing commitment to transparency we state our positions on different public policy issues affecting our business.

We are convinced that the societal challenges are best solved jointly by all relevant stakeholders.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *